RT Journal Article SR Electronic T1 De novo variants in the PSMC3 proteasome AAA-ATPase subunit gene cause neurodevelopmental disorders associated with type I interferonopathies JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.12.07.21266342 DO 10.1101/2021.12.07.21266342 A1 Ebstein, Frédéric A1 Küry, Sébastien A1 Most, Victoria A1 Rosenfelt, Cory A1 Boyer, Marie-Pier Scott- A1 van Woerden, Geeske M. A1 Besnard, Thomas A1 Papendorf, Jonas Johannes A1 Studencka-Turski, Maja A1 Wang, Tianyun A1 Hsieh, Tzung-Chien A1 Golnik, Richard A1 Baldridge, Dustin A1 Forster, Cara A1 de Konink, Charlotte A1 Teurlings, Selina M.W. A1 Vignard, Virginie A1 van Jaarsveld, Richard H. A1 Ades, Lesley A1 Cogné, Benjamin A1 Mignot, Cyril A1 Deb, Wallid A1 Jongmans, Marjolijn C.J. A1 Sessions Cole, F. A1 van den Boogaard, Marie-José H. A1 Wambach, Jennifer A. A1 Wegner, Daniel J. A1 Yang, Sandra A1 Hannig, Vickie A1 Brault, Jennifer Ann A1 Zadeh, Neda A1 Bennetts, Bruce A1 Keren, Boris A1 Gélineau, Anne-Claire A1 Powis, Zöe A1 Towne, Meghan A1 Bachman, Kristine A1 Seeley, Andrea A1 Beck, Anita E. A1 Morrison, Jennifer A1 Westman, Rachel A1 Averill, Kelly A1 Brunet, Theresa A1 Haasters, Judith A1 Carter, Melissa T. A1 Osmond, Matthew A1 Wheeler, Patricia G. A1 Forzano, Francesca A1 Mohammed, Shehla A1 Trakadis, Yannis A1 Accogli, Andrea A1 Harrison, Rachel A1 Deciphering Developmental Disorders Study A1 Care4Rare Canada Consortium A1 Rondeau, Sophie A1 Baujat, Geneviève A1 Barcia, Giulia A1 Feichtinger, René Günther A1 Mayr, Johannes Adalbert A1 Preisel, Martin A1 Laumonnier, Frédéric A1 Knaus, Alexej A1 Isidor, Bertrand A1 Krawitz, Peter A1 Völker, Uwe A1 Hammer, Elke A1 Droit, Arnaud A1 Eichler, Evan E. A1 Elgersma, Ype A1 Hildebrand, Peter W. A1 Bolduc, François A1 Krüger, Elke A1 Bézieau, Stéphane YR 2021 UL http://medrxiv.org/content/early/2021/12/07/2021.12.07.21266342.abstract AB A critical step in preserving protein homeostasis by the ubiquitin-proteasome system (UPS) is the recognition, binding, unfolding, and translocation of protein substrates by AAA-ATPase proteasome subunits for degradation by 26S proteasomes. Here, we identified fourteen different de novo missense variants in the PSMC3 gene encoding the AAA-ATPase proteasome subunit Rpt5 in twenty-two unrelated heterozygous subjects with an autosomal dominant form of neurodevelopmental delay and intellectual disability. Indeed, depletion of PSMC3 impaired reversal learning capabilities in a Drosophila model. The PSMC3 variants cause proteasome dysfunction in patient-derived cells by disruption of substrate translocation, proteotoxic stress and proteostatic imbalances, as well as alterations in proteins controlling developmental and innate immune programs. Molecular analysis confirmed the induction of cellular stress responses and dysregulated mitophagy along with an elevated type I interferon (IFN) signature. Our data define PSMC3 variants as the genetic cause of proteotoxic stress alerting the innate immune system to mount a type I IFN response and link neurodevelopmental syndromes to interferonopathies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the German Research Foundation (SFBTR167, RGT2719-PRO project B4) to EK, E-Rare project GENOMIT (Austrian Science Fund FWF, I4695-B) to JAM, in part, by US National Institutes of Health (NIH) grants (R01MH101221) and a grant from the Simons Foundation (SFARI #608045) to E.E.E.; E.E.E. is an investigator of the Howard Hughes Medical Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the CHU de Nantes ethics committee (Medical Genetic Research Programme number DC-2011-1399).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors